Etigilimab - Mereo BioPharma
Alternative Names: Anti-TIGIT monoclonal antibody; Anti-TIGIT monoclonal antibody - OncoMed; MPH-313; OMP-313M32Latest Information Update: 15 May 2024
At a glance
- Originator OncoMed Pharmaceuticals
- Developer Mereo BioPharma; OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase I/II Solid tumours
Most Recent Events
- 23 Oct 2023 Etigilimab - Mereo BioPharma is available for licensing as of 23 Oct 2023. http://sntpseditorial/adis2000www/
- 21 Sep 2023 Mereo BioPharma completes the Ib/II ACTIVATE basket trial in locally advanced or metastatic solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA and UK (IV) (NCT04761198)
- 30 Jun 2023 MD Anderson Cancer Center initiates phase-Ib/II trial for Ovarian cancer (Combination therapy, recurrent, Second-line therapy or greater) in USA